tapebrief
PODD · Q2 2025

PODD · Q3 2025 Earnings

Bullish

Insulet Corporation

Reported November 6, 2025

30-second summary

Insulet delivered $706M of revenue (+29.9% YoY, +29.3% CC for Total Omnipod), beating every prior-quarter guidance line and prompting another roughly four-point lift to the FY2025 Total Omnipod CC growth guide (to 29–30% from 25–28%). International accelerated to 39.9% YoY and Type 2 now exceeds 35% of U.S. new starts with prescriber base up 26% QoQ — the second-derivative signals investors needed before modeling 2026 are flashing positive. Drug Delivery decline came in at -31% vs. a -80%/-75% guide, a one-time-looking boost that management has not fully extrapolated into the FY (FY guide moved to -15%/-10%, implying a much steeper Q4 fall back).

Headline numbers

EPS

Q3 FY2025

$1.24

Revenue

Q3 FY2025

$0.71B

+29.9% YoY

Gross margin

Q3 FY2025

72.2%

Operating margin

Q3 FY2025

16.7%

Key financials

Q3 FY2025
MetricQ3 FY2025YoYQ2 FY2025QoQ
Revenue$0.71B+29.9%$0.65B+8.8%
EPS$1.24—$1.17+6.0%
Gross margin72.2%—69.7%+250bps
Operating margin16.7%—18.7%-200bps

Guidance

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
Total Revenue Growth (constant currency)Q3 FY202522% - 25%29.9%+4.9-7.9pts above guideBeat
U.S. Omnipod Revenue Growth (constant currency)Q3 FY202521% - 24%25.6%+1.6-4.6pts above guideBeat
International Omnipod Revenue Growth (constant currency)Q3 FY202533% - 36%39.9%+3.9-6.9pts above guideBeat
Total Omnipod Revenue Growth (constant currency)Q3 FY202524% - 27%29.3%+2.3-5.3pts above guideBeat
Drug Delivery Revenue Growth (constant currency)Q3 FY2025(80)% - (75)%-31.4%+43.6-48.6pts above guideBeat
Adjusted Operating MarginQ3 FY202517.0% - 17.5%17.1%in-lineMet

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Total Revenue Growth (constant currency)
FY2025
24% - 27%28% - 29%+1-5pts higherRaised
U.S. Omnipod Revenue Growth (constant currency)
FY2025
22% - 25%26% - 27%+1-5pts higherRaised
International Omnipod Revenue Growth (constant currency)
FY2025
34% - 37%38% - 39%+1-5pts higherRaised
Total Omnipod Revenue Growth (constant currency)
FY2025
25% - 28%29% - 30%+1-5pts higherRaised
Drug Delivery Revenue Growth (constant currency)
FY2025
(30)% - (25)%(15)% - (10)%+10-20pts higher (less negative)Raised

Reaffirmed unchanged this quarter: Gross Margin (~71%)

Segment KPIs

Q3 FY2025
SegmentQ3 FY2025YoY
U.S. Omnipod$0.497B+25.6%
International Omnipod$0.202B+39.9%
Drug Delivery$0.007B-31.4%
Total Omnipod Revenue$699.2M—

Other KPIs

Q3 FY2025
SegmentQ3 FY2025
Total Omnipod Growth (constant currency)29.3%
Adjusted Operating Margin17.1%
Adjusted EBITDA$160.0M
Adjusted EBITDA Margin22.7%

Management tone

Q1 (CEO transition risk) → Q2 (acceleration plan articulated) → Q3 (raise cadence institutionalized) — Ashley McEvoy's first two prints have collapsed the CEO-transition risk premium that overhung the stock into Q1.

The Q2 call introduced a "three times the beat" guidance philosophy that broke from Insulet's historical conservative-buffer cadence. Q3 confirms that wasn't a one-off CEO honeymoon move — it's now the operating model. The FY Total Omnipod CC guide has been raised in consecutive quarters by ~5 points each, and Q3 telegraphs Q4 strength rather than building cushion. New CFO Flavia Pease, on her first call, signaled disclosure framework evolution: "we might evolve a little bit the metrics that we focus on and guide to" — the kind of move companies make when they want investors looking at different scorecards heading into 2026.

Type 2 has shifted from "emerging opportunity" (Q1) to "first-mover with clinical parity" (Q2) to "flywheel" (Q3). Ashley in Q&A: "65% of DTC leads from uncalled-on providers" creates a "flywheel effect amplifying ROI." This matters because the bear case on Type 2 was that DTC spend would burn out at single-digit penetration; instead, DTC is generating self-reinforcing prescriber acquisition in an underpenetrated market (<mid-single-digits in Type 2). With Type 2 prescriber base up 26% in a single quarter and NCS up 100% YoY, the contribution is compounding faster than Q2 framing suggested.

Competitive positioning rhetoric hardened. Two analysts (J.P. Morgan, Baird) pressed on patch-pump entrants over the next 18–24 months; management's answer pivoted from defense to expansion, citing >$1B of cumulative supply chain investment, 47,000+ pharmacies, 300M covered lives, phone-control usage rising from 45% to 55% of U.S. users, and "one of strongest quarters in past 2 years for competitive conversions." The willingness to quantify competitive wins rather than wave them off is a confidence tell.

International tone shifted from "durable" to "still has room." Flavia explicitly knocked down distributor-stocking concerns: "no material or immaterial distributor stocking impacts" and confirmed Dash-to-Omnipod 5 conversion still has runway. International new customer starts +68% YoY underwrites the +37–40% Q4 guide rather than letting it look optimistic.

Risks management surfaced:

Regulatory mattersOperational mattersMacroeconomic environmentForeign exchange headwinds

Q&A highlights

Robbie Marcus · J.P. Morgan

Asked how Omnipod 5 is winning against increasing competition from new patch pump entrants, what is driving its success (form factor, algorithm, onboarding, etc.), and what gives confidence in sustained results.

Ashley attributed winning to: broad-based, balanced growth strategy; compelling science (SECURE T2D, RADIANT trials, real-world evidence); beloved brand with differentiated form factor; unique pay-as-you-go pharmacy access and affordability; resilient supply chain built over a billion dollars of investment; and balance sheet flexibility to invest in innovation.

Over $1 billion invested in supply chain over the yearsOmnipod available in 47,000+ US pharmacies90% of commercial plan coverage300 million covered lives accessible

David Roman · Goldman Sachs

Asked about Type 2 adoption trajectory one year into U.S. indication, current penetration status, and how DTC advertising investment translates to new patient starts and revenue.

Ashley described strong Type 2 momentum: 26% prescriber base growth in Q3, 100% YoY NCS growth, 26% QoQ growth. Strategy combines: strong science (SECURE T2D), leverage from existing Type 1 call point and endocrinologists, and meaningful DTC investments generating strong leads, including 65% from uncalled-on providers, creating a 'flywheel effect' amplifying ROI.

Type 2 prescriber base grew 26% in Q3Type 2 NCS up 100% year-over-yearType 2 NCS up 26% sequentially65% of DTC leads from uncalled-on providers

Travis Steed · Bank of America

Asked about puts and takes for 2026 guidance including Libre integration, Type 2 acceleration, and sustainability of record new starts; also asked to elaborate on revised guidance philosophy.

Ashley confirmed confidence in continued top-tier growth backed by proven leadership in large, under-penetrated markets; 2026 guidance to be provided on Q4 call per historical practice. Flavia explained new guidance philosophy: balanced outlook acknowledging risks and uncertainties plus upside opportunities; may evolve KPIs and metrics provided to shareholders in future; intent remains to guide with high confidence in achievement.

Clear pathway to continued top-tier growth in 2026Expected continued strong growth and improved profitability2026 guidance to be provided on Q4 callPotential evolution of metrics/KPIs for 2026 guidance

Jeff Johnson · BED

Asked about strategies to protect and extend competitive moat against two-piece patch pump competitors entering market over next 18-24 months.

Ashley focused on market expansion rather than defense, noting Omnipod drives majority of category growth. Strategy includes: continued investment in frictionless customer experience (DTC, prescriber engagement); pipeline innovations (phone control expansion from 45% to 55%); real-world evidence; supply chain diversification and resilience; staying ahead of demand and capacity curves.

Omnipod drives majority of AID category growthPhone control usage increased from 45% to 55% of U.S. Omnipod usersReal-world evidence showing improved outcomes with phone-controlled bolusingOne of strongest quarters in past 2 years for competitive conversions

Michael Pollack · Wolf Research

Asked about international volume dynamics as Omnipod 5 rolls out and converts from Dash, specifically whether there are first-fill dynamics, distributor stocking, or other volume influences to model for next couple of years.

Ashley emphasized robust, durable international growth driven primarily by volume and accelerated uptake from Dash-to-Omnipod 5 conversions with price realization benefit. Flavia explicitly confirmed no material distributor stocking impact in current or recent quarters; growth is fundamentally volume-driven with some price/mix benefit from product conversion, not supply-side inventory dynamics.

International revenue growth 39.9% constant currency in Q3International new customer starts up 68% YoYNo material or immaterial distributor stocking impactsPrimary driver is volume; price mix from Dash to Omnipod 5 conversion is secondary

Answers to last quarter's watch list

Q3 Total Omnipod growth clearing the high end of 24–27% CC — Came in at +29.3% CC, more than 230 bps above the high end. Management's "positive update" telegraph from Q2 delivered. Status: Resolved positively
U.S. new starts mix — Type 2 contribution building vs. plateauing — Type 2 now >35% of U.S. new starts (vs. ~one-third in Q2), with prescriber base +26% QoQ and NCS +100% YoY. The contribution is accelerating, not plateauing. Status: Resolved positively
Gross margin recovery toward ~71% — Q3 GM came in at 72.2%, up 250 bps from Q2's 69.7% and above the FY guide. FY guide raised to >71%; Q4 guided to >71%. Status: Resolved positively
Manufacturing capex disclosure with specific dollar figures and timing — Management referenced ongoing supply-chain investment (cumulative >$1B) but did not break out FY2026 capex dollars or timing for the expansion flagged in Q2. CFO indicated 2026 guidance comes on the Q4 call. Status: Continue monitoring
International CC growth holding above 33% — Came in at +39.9% YoY (constant currency growth materially above 33%); Q4 guide is +37–40%. Status: Resolved positively
Medicare DME competitive bidding update — Not addressed in the press release or Q&A discussed. No news is still good news here, but the silence isn't a resolution. Status: Continue monitoring

What to watch into next quarter

Whether Q4 Total Omnipod CC growth clears the +27–30% guide range. Management has now twice telegraphed and delivered upside; a mid-range Q4 print would mark a return to conservatism and could be read as deceleration.

2026 guidance framework on the Q4 call. Flavia hinted at KPI evolution — watch for changes to how new customer starts, Type 1 vs. Type 2 mix, or international disclosure are reported. Reframing disclosure is non-trivial signaling.

Type 2 contribution to U.S. new starts crossing 40%. At >35% this quarter (up from ~33% in Q2), the trajectory implies a 40%+ print in Q4 is plausible; failure to step up would be the first sign the flywheel is decelerating.

FY2026 adjusted operating margin trajectory vs. the "100+ bps per year" commitment. FY2025 will deliver well above 100 bps; the question is whether 2026 absorbs the accelerated manufacturing capex Q2 flagged, compressing the expansion rate.

Q4 gross margin landing above 71% as guided. Q3 ran at 72.2%; a step down below 71% in Q4 would surface a mix or investment dynamic management has not yet disclosed.

Drug Delivery Q4 actual landing inside the -95% to -85% guide. The legacy step-down resumes hard per the guide; meaningful upside here would suggest the FY range is still too conservative.

Sources

  1. Insulet Corporation Q3 FY2025 earnings press release, filed with SEC: https://www.sec.gov/Archives/edgar/data/1145197/000114519725000067/podd2025-09x30ex991.htm
  2. Insulet Corporation Q3 FY2025 earnings conference call transcript, November 6, 2025.

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.